Medline Industries, Inc.

In a complex healthcare world, Medline strives to help our customers achieve both clinical and financial success. We do that through a personalized approach to listen and better understand our customers’ needs in an environment that tirelessly demands lower costs and better outcomes. We are both a manufacturer and distributor with 1,600 direct sales reps who are dedicated points of contact for customers across the continuum of care. Because of our capabilities and engagement with other clinical and industry thought leaders, we deliver the most robust product portfolio and patient-care solutions to help healthcare providers perform at their very best.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

GT BIOPHARMA ANNOUNCES FDA DATA - GTB-3550, FOR TREATMENT OF HIGH-RISK MYELODYSPLASTIC SYNDROMES

GT Biopharma | December 23, 2020

news image

GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology organization focused in on innovative treatments dependent on the Company's restrictive NK cell engager (TriKE™) innovation stage is satisfied to report the introduction of extra interval information results for the Company's lead therapeutic competitor, GTB-3550, for the treatment of high-risk myelodysplastic syndromes (HR-MDS). Erica Warlick, M.D, Principal Investigator for the GTB-3550 clinical trial, i...

Read More

SOLIGENIX ANNOUNCED PUBLICATION OF PRE-CLINICAL IMMUNOGENICITY STUDIES FOR A NOVEL COVID-19 VACCINE

PR Newswire | July 29, 2020

news image

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of pre-clinical immunogenicity studies for its CiVax™ program (heat stable COVID-19 vaccine), demonstrating immunity of both broad-spectrum antibody and cell-mediated, rapid onset immunity is possible using the CoVaccine HT™ (CoVaccine) adjuvant.&nbs...

Read More

INDUSTRIAL IMPACT

LEICA BIOSYSTEMS AND LEAP THERAPEUTICS PARTNER ON COMPANION DIAGNOSTIC TO ADVANCE CARE FOR CANCER PATIENTS

Leap Therapeutics, Inc. | February 01, 2022

news image

Leica Biosystems, a cancer diagnostics company, has entered into an agreement with Leap Therapeutics, a biotechnology company, to develop a companion diagnostic to detect Dickkopf-related protein 1. The assay will be used to support clinical development of Leap Therapeutics' anti-DKK1 cancer therapy, DKN-01, currently being studied in clinical trials. DKK1 is a protein often implicated in cancer, enabling tumor cells to suppress the immune system and lead to unregulated growth...

Read More

YUFAN BIOTECHNOLOGIES AND ABOUND BIO SIGN MULTI-YEAR AGREEMENT TO DEVELOP NEXT GENERATION CAR T-CELL THERAPIES FOR CANCER

Yufan Biotechnologies | September 17, 2020

news image

Exhaustion of T-cells is a key reason why CAR T-cell therapy may fail to control cancer. Recent work led by Xuebin Liao, PhD, Professor of Pharmaceutical Science at Tsinghua University (Si et al., Cancer Cell 2020) shows that HPK1 (hematopoietic progenitor kinase 1) promotes T cell exhaustion via NFkB-Blimp1 activation and that blocking HPK1, either by gene knockout or by small-molecule inhibitors, is an attractive strategy to improve CAR T-cell immunotherapy. These innovative approaches a...

Read More
news image

MEDICAL

GT BIOPHARMA ANNOUNCES FDA DATA - GTB-3550, FOR TREATMENT OF HIGH-RISK MYELODYSPLASTIC SYNDROMES

GT Biopharma | December 23, 2020

GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology organization focused in on innovative treatments dependent on the Company's restrictive NK cell engager (TriKE™) innovation stage is satisfied to report the introduction of extra interval information results for the Company's lead therapeutic competitor, GTB-3550, for the treatment of high-risk myelodysplastic syndromes (HR-MDS). Erica Warlick, M.D, Principal Investigator for the GTB-3550 clinical trial, i...

Read More
news image

SOLIGENIX ANNOUNCED PUBLICATION OF PRE-CLINICAL IMMUNOGENICITY STUDIES FOR A NOVEL COVID-19 VACCINE

PR Newswire | July 29, 2020

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of pre-clinical immunogenicity studies for its CiVax™ program (heat stable COVID-19 vaccine), demonstrating immunity of both broad-spectrum antibody and cell-mediated, rapid onset immunity is possible using the CoVaccine HT™ (CoVaccine) adjuvant.&nbs...

Read More
news image

INDUSTRIAL IMPACT

LEICA BIOSYSTEMS AND LEAP THERAPEUTICS PARTNER ON COMPANION DIAGNOSTIC TO ADVANCE CARE FOR CANCER PATIENTS

Leap Therapeutics, Inc. | February 01, 2022

Leica Biosystems, a cancer diagnostics company, has entered into an agreement with Leap Therapeutics, a biotechnology company, to develop a companion diagnostic to detect Dickkopf-related protein 1. The assay will be used to support clinical development of Leap Therapeutics' anti-DKK1 cancer therapy, DKN-01, currently being studied in clinical trials. DKK1 is a protein often implicated in cancer, enabling tumor cells to suppress the immune system and lead to unregulated growth...

Read More
news image

YUFAN BIOTECHNOLOGIES AND ABOUND BIO SIGN MULTI-YEAR AGREEMENT TO DEVELOP NEXT GENERATION CAR T-CELL THERAPIES FOR CANCER

Yufan Biotechnologies | September 17, 2020

Exhaustion of T-cells is a key reason why CAR T-cell therapy may fail to control cancer. Recent work led by Xuebin Liao, PhD, Professor of Pharmaceutical Science at Tsinghua University (Si et al., Cancer Cell 2020) shows that HPK1 (hematopoietic progenitor kinase 1) promotes T cell exhaustion via NFkB-Blimp1 activation and that blocking HPK1, either by gene knockout or by small-molecule inhibitors, is an attractive strategy to improve CAR T-cell immunotherapy. These innovative approaches a...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us